


R&D Pipelines Covering a Wide Variety of Therapeutic Areas

Pre-Clinical			Phase 1			Phase 2	Phase 3	Approved
JS011 Undisclosed Tumors	JS120 IDH1 Tumors	JS209 CD112R+TIGIT Tumors	JS001sc PD-1 Tumors	JS015 DKK1 Tumors	JS112 Aurora A SCLC	Tifcemalimab BTLA Lung cancer, Melanoma, etc	JS109 PARP Ovarian cancer	Toripalimab PD-1 Tumors
JS013 CD93 Tumors	JS121 SHP2 Tumors	JS211 PD-L1+Undisclosed Tumors	JS003 PD-L1 Tumors	JS019 CD39 Tumors	JS113 EGFR 4th Gen NSCLC	JS005 IL-17A Psoriatic, spondylitis	Bevacizumab VEGF NSCLC	Adalimumab TNF- α Rheumatoid Arthritis, etc
JS018 IL-2 Tumors	JS122 FGFR2 Tumors	JS008 Undisclosed	JS006(TAB006) TIGIT Tumors	JS101 Pan-CDK Breast cancer, etc.	JS116 KRAS Tumors		Ongericimab PCSK9 Hyperlipidemia	Etesevimab* S protein COVID-19
JS104 Pan-CDK Breast cancer, etc	JS123 ATR Tumors	JS401 Undisclosed (RNAi) Metabolic diseases	JS007 CTLA-4 Lung cancer, melanoma	JS105 PI3K- α Breast cancer, renal cell cancer	JS201 PD-1+TGF- β Tumors			JT001(VV116) RdRp COVID-19
JS114 Nectin4 ADC Tumors	JS205 EGFR+cMet Tumors	JS010 CGRP Migraine	JS009(TAB009) CD112R/PVRIG Tumors	JS107 Claudin18.2 ADC Gastrointestinal cancer	JS203 CD3+CD20 Tumors			
JS115 BCMA ADC Multiple myeloma	JS206 IL2+PD-1 Tumors	JT003(VV993) 3CLpro COVID-19	JS012 Claudin 18.2 Gastric cancer	JS108 TROP2 ADC TNBC	JS103 Uricase Hyperuricacidemia			
	JS207 PD-1+VEGF Tumors	JT109 Vaccine ZIKA Virus	JS014 IL-21 Tumors	JS110 XPO1 Multiple myeloma, etc	UBP1213sc BlyS Systemic lupus erythematosus			
				JS111 EGFR exon 20 NSCLC	JS026 S protein COVID-19			



The pipeline update as of Feb. 28, 2023

* Received FDA Emergency Use Authorization in 2021